ReNewVax are pleased to announce the appointment of Dr Simon Cruwys and Dr. Carolyn Horrocks to the Board of the Company.
With over 30 years experience in academic and industrial research, Simon has been involved with ReNewVax since its inception. As Head of the Innovative Medicines Unit at Grünenthal Innovation, Simon led a team responsible for in-licensing molecules and delivering them to Clinical proof of concept. Prior to Grünenthal, Simon worked for AstraZeneca where he was lead for both small molecule and antibody projects, with a track record of delivery from Lead Identification through to clinical validation. He is currently Director of Pharmacology at TherapeutAix UG.
Having recently been appointed as Head of IP Commercialisation Health with the University of Liverpool’s Commercialisation team, Carolyn is taking over as University’s representative on the Board.
Emma Nolan, Head of the Enterprise Team at the University of Liverpool has stepped down from the Board.
Neil Murray, CEO, said, “I’d like to welcome Carolyn and Simon to the ReNewVax Board and look forward to working with them to drive the Company’s growth.
“On behalf of the Board and team at ReNewVax, I’d like to thank Emma for her great contribution to the success of the business as we navigated the early stages of our spin out from the University.”